Dr Werner Lanthaler appointed Chairman of the Supervisory Board of HAL Allergy

Dr Werner Lanthaler brings over two decades of experience in biotech and pharmaceuticals, specializing in drug discovery and development. As founder and CEO of Wlanholding, he focuses on building and investing in high-tech life science and sustainability innovators. Previously, as CEO of Evotec SE, he played a pivotal role in shaping the company into a global leader. Before, Dr Lanthaler helped to grow Intercell AG into a major vaccine player as its CFO. He started his professional career at the Federation of Austrian Industry and the consulting firm McKinsey & Company.

Dr Ernest-W. Droege, CEO of Droege Group as the shareholder of HAL Allergy, states: ‘We are pleased to welcome Dr Werner Lanthaler to our Supervisory Board. His strategic vision, his deep expertise in the biotechnology sector and his far-reaching international network will make a significant contribution to further strengthening HAL Allergy's position in existing markets and to the company's continued international success.’

The appointment of Dr Lanthaler underlines HAL Allergy's clear commitment to further developing allergen immunotherapy. With a comprehensive portfolio of allergen-specific immunotherapy products (AIT) and a strong focus on therapeutic applications, HAL Allergy is very well positioned to effectively treat allergic diseases.

Dr Lanthaler on his new role: ‘I look forward to becoming part of a strong team and supporting HAL Allergy’s mission of improving the lives of individuals affected by allergic diseases. Implications on patients with allergies are huge. Great to see the impact of HAL Allergy and its products on the quality of life for patients.”